Skip to main content

Table 1 Characteristics and differences by serum CA 19-9 levels in patients with advanced-stage lung adenocarcinoma

From: The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Patient characteristics Total n (%) (n = 246) CA 19-9 positive n (%) (n = 76) CA 19-9 negative n (%) (n = 170) P
Age (years)
 SD 10.4 10.7 10.2 0.160
 Mean 67.1 68.5 66.5
Sex
 Male 154 (63) 47 (62) 107 (63) 0.887
 Female 92 (37) 29 (38) 63 (37)
Smoking status
 Never 101 (41) 29 (38) 72 (42) 0.577
 Current or former 145 (59) 47 (62) 98 (58)
ECOG PS
 0 or 1 184 (75) 46 (61) 138 (81) <0.001
 2–4 62 (25) 30 (39) 32 (19)
Stage
 IIIB 26 (11) 6 (8) 20 (12) 0.501
 IV 220 (89) 70 (92) 150 (88)
EGFR status
 Mutated 100 (41) 30 (39) 70 (41) 0.888*
  Exon 19 deletion 45 (18) 16 (21) 29 (17)
  Exon 21 point mutation 48 (20) 11 (14) 37 (22)
  Others 7 (3) 3 (4) 4 (2)
 WT or uninvestigated 146 (59) 46 (61) 100 (59)
Inflammatory lung disease
 Present 22 (9) 10 (13) 12 (7) 0.147
 Absent 224 (91) 66 (87) 158 (93)
Serum CEA
 Positive 163 (66) 53 (70) 110 (65) 0.469
 Negative 83 (34) 23 (30) 60 (35)
Serum CYFRA 21-1
 Positive 155 (63) 59 (78) 96 (56) 0.002
 Negative 91 (37) 17 (22) 74 (44)
Chemotherapy
 Platinum doublet 170 (69) 43 (57) 127 (75) 0.007
 Others 76 (31) 33 (43) 43 (25)
  1. CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CYFRA 21-1 cytokeratin 19 fragments, ECOG PS Eastern Cooperative Oncology Group Performance Status, EGFR epidermal growth factor receptor gene, SD standard deviation, WT wild-type
  2. *Comparison between patients with mutated EGFR and those with WT or uninvestigated EGFR